|
|
 |
|
Viewing report
|
|
|
|
2003 Cardiovascular Market Update: Part 2 - Antithrombotics
Datamonitor, Aug 2003, Pages: 70
Introduction
According to IMS Health data, global sales of cardiovascular and antithrombotic drugs, i.e. anti-hypertensives, anti-dyslipidemics, antithrombotics and cardiac therapies, reached $72.6bn in 2002. However, competition within each of the four therapy areas is fierce, with many leading brands facing the threat of generic competition and other key patents due to expire over the next five years.
Scope
- Provide a reference tool for the cardiovascular market, including a comprehensive overview of the antithrombotics market
- Detail sales trends from 2001 to 2002 by therapy area, by antithrombotic class and by top 10 antithrombotic brands
- Summarize key events in the antithrombotics market in the first half 2003 and analyze their impact on the future dynamics of the market
- Identify the key late stage developmental compounds that have the potential to achieve blockbuster status within the antithrombotics market
Report Highlights
The antithrombotics market continues to show impressive growth, driven by the rapid uptake of Plavix (clopidogrel), which achieved sales of $2.5 billion in 2002
As well as growth in sales of Plavix, growth in the Lmwh market continues as physicians switch away from UFH to the newer Lmwh brands
In the future, the launch of AstraZeneca’s Exanta (ximelagatran) may challenge Plavix in certain indications (e.g. post-acs) but is expected to generate significant revenues in the stroke prevention in atrial fibrillation market
Reasons to Purchase
- Gain an overview of the dynamics of the antithrombotic market in 2003
- Understand the key events impacting the future dynamics and the leading brands within this market
- Recognize the threats facing the leading products and identify key opportunities for R&D
Customers who bought this item also bought
Pipeline Insight: Antithrombotics - Entering the Era of Exanta
The Asian Cardiovascular Market Outlook to 2010
The Eastern European Cardiovascular Market Outlook to 2010
The Latin American Cardiovascular Market Outlook to 2010
Pipeline Insight: Antithrombotics - Anticoagulants And Antiplatelets Have Blockbuster Potential
Cardiovascular Devices Pipeline Analysis: Innovation and Consolidation Intensify Competition February 22
Leading Cardiovascular Players 2002 - Portfolios Requiring Replacement Blockbusters
Healthcare Review: Cardiovascular - September 2002
|
|
|
|
